Antibacterial agent for treating infectious diseases of bacterial origin

Abstract

The invention relates to medicine, namely to the antimicrobial agent for the treatment of infectious bacterial diseases including hospital infections and drug-resistant TB which represents the ion nanostructured complex (INSC) synthesized from carbohydrates proteins and/or polypeptides (albumins, interleukins, interferons, signaling proteins, etc), which are to enhance the antimicrobial activity in vivo, by activating immune cells that contain at least one terminal amino acid such as Phe, Ala, Val, Ala, Leu, Ile, and others with electron-donor functional groups, iodine and halides of the alkali and alkaline earth elements in the fourth stage at a certain ionic strength; an antibacterial agent increases: the susceptibility of bacteria, including antibiotic-resistant, to antibiotics; activity of monocytes and macrophages; efficiency of antibiotic treatment of hospital infections and drug-resistant TB; it also has antiviral activity, stimulates hematopoietic function of bone marrow; has an antitumor effect and radioprotective properties; in acceptable concentrations of components can be used as non-pharmaceutical agent (BAFS or parapharmaceutical); is presented in the pharmacological form suitable for parenteral, oral, external, or other application. INSC has the formula [{(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl−)y+x+k] with M=30-300 kDa.

1 . Antibacterial agent for treating bacterial infectious diseases including hospital infections and drug resistant TB, which represents ionic nanostructured complex formed by proteins and/or polypeptides. Carbohydrates, salts of alkali and alkaline-earth metals and iodine intercalated into them, characterized in that the proteins and/or polypeptides of ion nanostructured complex contain at least one chain-terminal amino acid with electron-donor functional groups. 
     
     
         2 . Antibacterial agent according to  claim 1 , characterized in that interleukins are used as proteins, and chain-terminal amino acids are Phe, Ala, Val, Ala, Leu, Ile, etc. 
     
     
         3 . Antibacterial agent according to  claim 1 , characterized in that the antimicrobial agent increases bacterial susceptibility to antibiotics, including antibiotic-resistant bacteria. 
     
     
         4 . Antibacterial agent according to  claim 1 , characterized in that it increases the efficiency of antibiotic treatment for bacterial infectious diseases, including hospital infections and drug-resistant TB. 
     
     
         5 . Antibacterial agent according to  claim 1 , characterized in that it has antiviral action. 
     
     
         6 . Antibacterial agent according to  claim 1 , characterized in that it has immunogenic activity, increasing the activity of monocyte-macrophages and cytotoxic T-lymphocytes. 
     
     
         7 . Antibacterial agent according to  claim 1 , characterized in that it stimulates the hematopoietic function of bone marrow. 
     
     
         8 . Antibacterial agent according to  claim 1 , characterized in that it possesses antineoplastic action. 
     
     
         9 . Antibacterial agent according to  claim 1 , characterized in that it has radioprotective properties. 
     
     
         10 . Antibacterial agent according to  claim 1 , characterized in that INSC has the following formula: [{(Ln(MeI3)+)y[Me(Lm)I]+x}(Cl−)y+x+k] with M=30-300 kDa. 
     
     
         11 . Antibacterial agent according to  claim 1 , characterized in that it is presented in a pharmaceutical form suitable for parenteral, oral, external or other application. 
     
     
         12 . Antibacterial agent according to  claim 1 , characterized in that in certain acceptable concentrations of components it is a non-medicinal agent. 
     
     
         13 . Method of producing the antibacterial agent according to  claim 1 , comprising complexation reaction of carbohydrates and proteins with metal salts, and intercalation of iodine into complex at ionic strength from 5·10-4 to 15, characterized in that introduction of immunotropic proteins is carried out as an individual stage after iodine intercalation of 5-95%.